Impacting society, creating change
Technologies developed at Ohio State are changing the world. Learn more about the startups that are currently a part of the Ohio State portfolio or download our printable catalog (as of June 30, 2019).
Search for a Startup below
OncoImmune specializes in therapeutics for cancer, inflammation and autoimmune diseases. OncoImmune’s lead compound CD24Fc is a clinical stage asset targeting the CD24-Siglec axis that regulates host inflammatory response to tissue injuries. This has broad implications in the pathogenesis of autoimmune diseases, cancer and graft-versus-host disease. OncoImmune has received orphan drug designation for CD24Fc in both the United States and Europe.
NervGen Pharma Corp. is a regenerative medicine company dedicated to the advancement of innovative therapeutics for the treatment of nerve damage, including spinal cord and peripheral nerve injuries. The company’s technology targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that inhibits nerve regeneration. Inhibition of the PTPσ receptor promotes regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions.
NanoMedical Systems (NMS) is commercializing silicon-based medical nanotechnology products for personalized medicine. The company’s Personalized Molecular Drug-delivery System (PMDS) is an implantable capsule with a nano-channel chip that provides sustained, controlled drug release within the optimal therapeutic range. This translates to improved safety and therapeutic efficacy, ultimately resulting in improved patient outcomes. The company licensed technology from Ohio State and the University of Texas.
Medeoryx is commercializing direct tissue reprogramming utilizing tissue nanotransfection (TNT) technology that can deliver reprogramming cargo directly into adult cells in milliseconds, without the need for viral delivery vectors. TNT induces direct in vivo cellular reprogramming and is applicable to both skin and surgically-accessible tissue. The technology has applications to improve the treatment of diabetes, cancer, wound healing, and limb ischemia.
Inthera Bioscience AG is a pre-clinical stage oncology company developing small-molecule inhibitors of protein-protein interactions. The company utilizes a proprietary technology platform to rationally design orally available molecules that display hot spot residues on a non-peptidic backbone, merging the versatility of small molecules with the specificity of biologics. The initial focus is reactivation of the p53 tumor suppressor pathway in HPV-associated cancers.